Director, Early Preclinical Development - Gene Therapy
Eli Lilly and Company
Boston, MA, United States
Yukako Asai, PhD is Deirector, Early Preclinical Development - Gene Therapy at Eli Lilly and Company. Her current role involves developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with hearing loss. Yukako Asai received a PhD from Nagoya University, Japan and has more than 20 years of experience in hearing research at academia and industry. Yukako has presented her work at numerous national and international conferences.
Disclosure information not submitted.
Rationale and Trial Design for an AK-antiVEGF Gene Therapy Trial for Vestibular Schwannoma
Monday, October 13, 2025
9:48 AM - 9:54 AM EDT